Close Menu
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Advertisement
X (Twitter) LinkedIn Facebook
X (Twitter) LinkedIn Facebook YouTube
OncologyTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
Subscribe
OncologyTube
Home » Privacy Policy for OncologyTube.com

Privacy Policy for OncologyTube.com

Ask about FDA oncology approvals, clinical trials, and treatment guidelines.

Last Updated: September 23, 2025

Welcome to OncologyTube.com (“we,” “us,” or “our”). We are committed to protecting your privacy when you use our services, including our oncology content platform at https://oncologytube.com and logistics services for Medicus Networks, Inc. (the “Services”). By using our Services, you agree to this Privacy Policy.

1. Information We Collect

We collect:

  • Personal Information: Name, email, phone number (e.g., for user/driver signups).
  • Usage Data: IP address, device info, pages visited (via cookies).
  • Job/Health Data: Driver availability or health-related content you share.

2. How We Use Your Information

We use your data to:

  • Provide and improve our Services (e.g., job notifications, content).
  • Send optional SMS/text messages for job alerts and updates with your consent.
  • Analyze usage for enhancements.
  • Comply with legal obligations.

3. SMS Communications

We offer optional SMS notifications for Medicus Networks, Inc. drivers. Consent is collected via a separate, optional checkbox on our signup form at https://oncologytube.com/newsletter: ‘☑ Optional: I agree to receive text messages from Medicus Networks, Inc. for job assignments, shift updates, and alerts. Msg & data rates may apply. Reply STOP to unsubscribe or email [email protected].’ This is not required for Service use. Opt-out is available via STOP or contact.

4. How We Share Your Information

We do not sell your data. We may share with:

  • Service Providers: Vendors for hosting/analytics (confidentiality bound).
  • Legal Requirements: If subpoenaed or required by law.
  • Business Transfers: During mergers or asset sales.
  • Your Consent: With your approval.

5. Cookies and Tracking

Cookies enhance your experience. Disable via browser, but some features may not work.

6. Your Choices and Rights

You can:

  • Access, update, or delete your data.
  • Opt out of SMS by replying STOP. Contact: [email protected].

7. Data Security

We use reasonable security measures, but no system is fully secure.

8. Third-Party Links

We’re not responsible for third-party site privacy practices.

9. Children’s Privacy

Not for users under 13. We delete such data if collected.

10. International Users

Data is hosted in the US. Using our Services consents to this transfer.

11. Changes to Policy

Updates posted here with a new “Last Updated” date. Review periodically.

12. Contact Us

Email: [email protected] Address: 45121 Morgan Heights Dr, Temecula, CA 92592

Connect With Us on Social
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube

Latest FDA Oncology Updates

Accepted for Review Oncology Press Release

FDA Accepts NDA for TLX101-Px (Pixclara®) - PR Newswire

FDA Accepts NDA for TLX101-Px (Pixclara®). (PRNewsfoto/Telix Pharmaceuticals ... cancer), and has assigned a PDUFA goal date of September 11, 2026 ...

Filed: Sep 11, 2026 View source on FDA.gov →
ODAC Meeting Oncology FDA ODAC

April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee

Event Title. April 30, 2026: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement. April 30, 2026 · On This Page · Agenda · Meeting Materials.

Meeting: Apr 30, 2026 View source on FDA.gov →
PDUFA Date Oncology Press Release

Savara Announces the U.S. Food & Drug Administration (FDA) Has ...

Such statements include, but are not limited to, statements related to the target PDUFA action date. Savara may not actually achieve any of the matters ...

View source on FDA.gov →
Approval Heme FDA OCE

FDA approves nivolumab with chemotherapy for Hodgkin lymphoma

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent ...

View source on FDA.gov →
News Oncology FDA OCE

FDA Oncology Center of Excellence Presents Conversations on ...

FDA Oncology Center of Excellence Presents Conversations on Cancer: Oncology Nurses - Frontliners in Oncology May 6, 2026.

View source on FDA.gov →
News Oncology FDA OCE

FDA Schedules Public Meeting on the Commissioner's National ...

... Oncology Center of Excellence, as well as a presiding officer. Requests to speak are due by April 24 at 11:59 p.m. The FDA is also soliciting written ...

View source on FDA.gov →
Approval GYN FDA.gov

FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

Approved: Mar 25, 2026 View source on FDA.gov →
Approval Heme FDA.gov

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

Approved: Mar 20, 2026 View source on FDA.gov →
Recent Posts
  • Does QHS-5132 Signal a Biomarker-Agnostic Shift in Ovarian Cancer Treatment?
  • Is Alisertib the New Standard for Overcoming Resistance in KRAS G12C-Mutant NSCLC?
  • Can Zoldonrasib Redefine Treatment for KRAS G12D NSCLC?
  • Are We Under-Treating PE in Cancer Patients?
  • Is MammaPrint High Risk the New Standard for Guiding Immunotherapy?
X (Twitter) LinkedIn Facebook YouTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising & Services – Media Kit 2025 OncologyTube.com
    • Oncology Press Release Distribution
© 2026 Copyright Protected Medicus Networks, Inc. Privacy Policy

Type above and press Enter to search. Press Esc to cancel.